Jingxin Yan - Department of Interventional Therapy, Affiliated hospital of Qinghai University, Xining, China & Department of Postgraduate, Qinghai University, Xining, China
Ting Li - Department of Orthopedics, Sichuan People's Hospital, Chengdu, China & Department of Postgraduate, Chengdu Medical College, Chengdu, China
Yaxuan Wang - Department of Radiology, Chengdu Medical College, Chengdu, China
Hao Zhu - Department of Ultrasound Medicine, People’s Hospital of Tibet Autonomous Region, Lhasa, China ; Department of Postgraduate, Tibet University, Lhasa, China
Ruihong Liu - Nanchong Central Hospital, North Sichuan Medical College, Nanchong, China
Zhenwu Lei - Department of Interventional Therapy, Affiliated hospital of Qinghai University, Xining, China
Yingxing Guo - Department of Interventional Therapy, Affiliated hospital of Qinghai University, Xining, China

Introduction: A systematic review and meta-analysis was conducted to assess the efficacy and safety of iodine-۱۲۵ implantation combined with gemcitabine in the treatment of advanced pancreatic cancer. Methods:  PubMed,  Chinese  National  Knowledge  Infrastructure  database  (CNKI), Cochrane Library, Embase, and Wanfang database through Oct ۲۰۲۰ were searched for randomized controlled trials (RCTs) and retrospective studies assessing the efficacy and  safety  of  iodine-۱۲۵  implantation  combined  with  gemcitabine  in  the  treatment  of advanced  pancreatic  cancer.  The  main  outcome  measures  included  the  overall  remission [complete  response  (CR)+partial  response  (PR)]  rate,  overall  survival  (OS),  hypofunction of the liver, clinical benefit response (CBR) rate, survival rate, and adverse events. Results:   Totally,   ۱۹   studies   involving   ۱۴۹۶   patients   were   included   in   the   current systematic review and meta-analysis. The pooled results showed that efficacy and safety of  patients  treated  with  Iodine-۱۲۵  combined  with  gemcitabine  were  superior  to  those undergoing  gemcitabine  alone:  overall  remission  (CR+PR)  rate  [odds  ratio  (OR)=۳.۱۰, ۹۵% confidence interval (CI): ۲.۴۰, ۴.۰۰; P<۰.۰۰۰۰۱], OS [hazard ratio (HR)=۰.۵۶, ۹۵% CI: ۰.۴۷, ۰.۶۸; P<۰.۰۰۰۰۱], hypofunction of liver (OR=۱.۰۸, ۹۵% CI: ۰.۶۷, ۱.۷۴; P=۰.۷۵), CBR rate (OR=۳.۸۵, ۹۵% CI: ۲.۸۳, ۵.۲۲; P<۰.۰۰۰۰۱), survival rate of six months (OR=۳.۴۴ ۹۵% CI: ۱.۸۳, ۶.۴۶) and survival rate of ۱۲ months (OR=۲.۶۷, ۹۵% CI: ۱.۶۸, ۴.۲۶). And there was no statistical association in adverse events between the groups. Conclusions:   The   combination   of   iodine-۱۲۵   seed   implantation   and   gemcitabine significantly prolonged the survival of patients with pancreatic cancer, compared with the gemcitabine alone, indicating a better prognosis.

Iodine-۱۲۵, Pancreatic Neoplasms, Meta-Analysis, Gemcitabine